Skip to content
drillr.ai
Sign up

CGTX

COGNITION THERAPEUTICS INC

NASDAQ · Healthcare · Biotechnology · US

$1.04
−1.89%
Ask drillr

  • Aug 7, 2026, 00:13 UTC

    Cognition Therapeutics, Inc. reported a second-quarter loss of $0.04 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and the year-ago loss of $0.11 per share.

    Source:

  • Jun 24, 2026, 11:49 UTC

    Cognition Therapeutics received written feedback from the FDA agreeing that psychosis associated with dementia with Lewy bodies could be an approvable outcome and aligning on key aspects of a pivotal trial for Zervimesine (CT1812).

    Source: